VIR Stock Analysis: Buy, Sell, or Hold?
VIR - Vir Biotechnology, Inc. Common Stock
$9.02
0.06 (0.67%)
▲
5d:
+0.33%
30d:
+1.23%
90d:
+54.45%
BUY
MODERATE Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 06, 2026
Smart Money Accumulation
VIR is down 9.6% this week, but smart money is accumulating calls. Top strike: $11 2026-05-15 with 73 OI. Call ratio: 94% View Scanner →
Strength: 9.2/10
Get Alerted When VIR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: VIR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: VIR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: VIR is currently trading at $9.02, which is considered fair relative to its 30-day fair value range of $8.66 to $9.71.
Technical Outlook: Technically, VIR is in a strong uptrend. Immediate support is located at $8.26, while resistance sits at $9.55.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.78 (+130.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VIR is in a strong uptrend. Immediate support is located at $8.26, while resistance sits at $9.55.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.78 (+130.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$8.66 -
$9.71
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 130.4% below Wall St target ($20.78)
Fair Price Analysis
30-Day Fair Range
$8.66 -
$9.71
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$8.26
Resistance Level
$9.55
Current Trend
Strong Uptrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.01
Wall Street Target
$20.78
(+130.4%)
Revenue Growth (YoY)
417.8%
Earnings Growth (YoY)
58.5%
Share & Embed Analysis
Last updated: April 02, 2026 5:39 AM ET
Data refreshes hourly during market hours. Next update: 6:39 AM
Data refreshes hourly during market hours. Next update: 6:39 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VIR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Vicki L Sato
SELL
22000 shares
2026-03-02
Verneuil Vanina De
SELL
13700 shares
2026-02-25
Mark Eisner
SELL
1889 shares
2026-02-25
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 52 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 66 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 52 HOLD |
